



## Complete Summary

---

### TITLE

Initial management of abnormal cervical cytology (Pap smear) and human papillomavirus (HPV) testing: percentage of adult women diagnosed with initial abnormal cervical cytology of atypical squamous cells of undetermined significance (ASCUS) with high-risk HPV type who have follow-up colposcopy within six months of abnormality identified.

### SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Initial management of abnormal cervical cytology (Pap smear) and HPV testing. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2008 Oct. 32 p. [63 references]

## Measure Domain

### PRIMARY MEASURE DOMAIN

Process

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the [Measure Validity](#) page.

### SECONDARY MEASURE DOMAIN

Does not apply to this measure

## Brief Abstract

### DESCRIPTION

This measure is used to assess percentage of adult women diagnosed with initial abnormal cervical cytology of atypical squamous cells of undetermined significance (ASCUS) with high-risk human papillomavirus (HPV) type who have follow-up colposcopy within six months of abnormality identified.

### RATIONALE

The priority aim addressed by this measure is that all women who undergo cervical cytologic analysis and receive an abnormal cervical cytology result will receive appropriate clinical follow-up.

## PRIMARY CLINICAL COMPONENT

Cervical cytology; atypical squamous cells of undetermined significance (ASCUS); high-risk human papillomavirus (HPV) type; colposcopy

## DENOMINATOR DESCRIPTION

Number of women with an initial abnormal cervical cytology of atypical squamous cells of undetermined significance (ASCUS) with high-risk human papillomavirus (HPV) type identified by International Classification of Diseases, Ninth Revision (ICD-9) code 795.05 within reporting quarter

## NUMERATOR DESCRIPTION

Number of women with follow-up colposcopy within six months (see the related "Numerator Inclusions/Exclusions" field in the Complete Summary)

### Evidence Supporting the Measure

#### EVIDENCE SUPPORTING THE CRITERION OF QUALITY

- A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

#### NATIONAL GUIDELINE CLEARINGHOUSE LINK

- [Initial management of abnormal cervical cytology \(Pap smear\) and HPV testing.](#)

### Evidence Supporting Need for the Measure

#### NEED FOR THE MEASURE

Unspecified

### State of Use of the Measure

#### STATE OF USE

Current routine use

#### CURRENT USE

Internal quality improvement

### Application of Measure in its Current Use

#### CARE SETTING

Physician Group Practices/Clinics

**PROFESSIONALS RESPONSIBLE FOR HEALTH CARE**

Physicians

**LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED**

Group Clinical Practices

**TARGET POPULATION AGE**

Unspecified

**TARGET POPULATION GENDER**

Female (only)

**STRATIFICATION BY VULNERABLE POPULATIONS**

Unspecified

**Characteristics of the Primary Clinical Component**

**INCIDENCE/PREVALENCE**

Unspecified

**ASSOCIATION WITH VULNERABLE POPULATIONS**

Unspecified

**BURDEN OF ILLNESS**

Unspecified

**UTILIZATION**

Unspecified

**COSTS**

Unspecified

**Institute of Medicine National Healthcare Quality Report Categories**

**IOM CARE NEED**

Staying Healthy

## **IOM DOMAIN**

Effectiveness  
Timeliness

### **Data Collection for the Measure**

## **CASE FINDING**

Users of care only

## **DESCRIPTION OF CASE FINDING**

Women with an initial abnormal cervical cytology result of atypical squamous cells of undetermined significance (ASCUS) with high-risk human papillomavirus (HPV) type isolated

Identify women with abnormal Pap smear results of ASCUS with high-risk HPV type by International Classification of Diseases, Ninth Revision (ICD-9) code. If you are doing this measure quarterly, select a three-month target period that is six to nine months prior. For example, if this measure is to be collected in June, select a target period of October through December of the previous year.

The suggested time frame for data collection is quarterly.

## **DENOMINATOR SAMPLING FRAME**

Patients associated with provider

## **DENOMINATOR INCLUSIONS/EXCLUSIONS**

### **Inclusions**

Number of women with an initial abnormal cervical cytology of atypical squamous cells of undetermined significance (ASCUS) with high-risk human papillomavirus (HPV) type identified by International Classification of Diseases, Ninth Revision (ICD-9) code 795.05 within reporting quarter

### **Exclusions**

Unspecified

## **RELATIONSHIP OF DENOMINATOR TO NUMERATOR**

All cases in the denominator are equally eligible to appear in the numerator

## **DENOMINATOR (INDEX) EVENT**

Clinical Condition

## **DENOMINATOR TIME WINDOW**

Time window is a single point in time

## **NUMERATOR INCLUSIONS/EXCLUSIONS**

### **Inclusions**

Number of women with follow-up colposcopy within six months\*

\*Women identified in the denominator who have had an encounter with a Current Procedure Terminology (CPT) code of 57452, 57454, 57455, 57456, 57460, 57461 within six months of initial abnormal Pap results.

Review the visit data for the women identified in the target period for clinical follow-up using the International Classification of Diseases, Ninth Revision (ICD-9) code listed. Many medical groups will have access for this data through their clinical data systems and access the CPT codes through their administrative data system.

For those women who have not received a follow-up colposcopy, a chart audit can be performed to determine if care was received from an outside provider. Documentation of follow-up in the chart will be considered meeting the criteria of the measure.

### **Exclusions**

Unspecified

## **MEASURE RESULTS UNDER CONTROL OF HEALTH CARE PROFESSIONALS, ORGANIZATIONS AND/OR POLICYMAKERS**

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

## **NUMERATOR TIME WINDOW**

Fixed time period

## **DATA SOURCE**

Administrative data  
Medical record

## **LEVEL OF DETERMINATION OF QUALITY**

Individual Case

## **PRE-EXISTING INSTRUMENT USED**

Unspecified

## Computation of the Measure

### SCORING

Rate

### INTERPRETATION OF SCORE

Better quality is associated with a higher score

### ALLOWANCE FOR PATIENT FACTORS

Unspecified

### STANDARD OF COMPARISON

Internal time comparison

## Evaluation of Measure Properties

### EXTENT OF MEASURE TESTING

Unspecified

## Identifying Information

### ORIGINAL TITLE

Percentage of adult women diagnosed with initial abnormal cervical cytology of ASCUS with high-risk HPV type who have follow-up colposcopy within six months of abnormality identified.

### MEASURE COLLECTION

[Initial Management of Abnormal Cervical Cytology \(Pap Smear\) and HPV Testing Measures](#)

### DEVELOPER

Institute for Clinical Systems Improvement

### FUNDING SOURCE(S)

The following Minnesota health plans provide direct financial support: Blue Cross and Blue Shield of Minnesota, HealthPartners, Medica, Metropolitan Health Plan, PreferredOne and UCare Minnesota. In-kind support is provided by the Institute for Clinical Systems Improvement's (ICSI) members.

## **COMPOSITION OF THE GROUP THAT DEVELOPED THE MEASURE**

*Work Group Members:* Brendon Cullinan, MD (Work Group Leader) (Hennepin County Medical Center) (Family Medicine); Jeanne M. Anderson, MD (Family HealthServices Minnesota) (Family Medicine); Amy Nelson, MD (Sanford Health) (Family Medicine); Melissa A. Geller, MD (University of MN) (Gynecology/Oncology); Dale Akkerman, MD (Park Nicollet Health Services) (Ob/Gyn); Brigitte Barrette, MD (Mayo Clinic) (Ob/Gyn); Ashley Briggs, MD (Sanford Health) (Ob/Gyn); Jeff Raines, MD (Fairview Health Services) (Ob/Gyn); Lachlan Smith, MD (Affiliated Community Medical Center) (Ob/Gyn); Jane Suska, CNP (HealthPartners Central MN Clinics) (Ob/Gyn); Corrine Esch, RN (HealthPartners Medical Group) (Nursing); R. Paul Weatherby, MD (Park Nicollet Health Services) (Pathology); Sylvia Robinson, BSN, MBA (Institute for Clinical Systems Improvement) (Measurement/Implementation Advisor); Linda Setterlund, MA, CPHQ (Institute for Clinical Systems Improvement) (Facilitator)

## **FINANCIAL DISCLOSURES/OTHER POTENTIAL CONFLICTS OF INTEREST**

ICSI has adopted a policy of transparency, disclosing potential conflict and competing interests of all individuals who participate in the development, revision and approval of ICSI documents (guidelines, order sets and protocols). This applies to all work groups (guidelines, order sets and protocols) and committees (Committee on Evidence-Based Practice, Cardiovascular Steering Committee, Women's Health Steering Committee, Preventive & Health Maintenance Steering Committee and Respiratory Steering Committee).

Participants must disclose any potential conflict and competing interests they or their dependents (spouse, dependent children, or others claimed as dependents) may have with any organization with commercial, proprietary, or political interests relevant to the topics covered by ICSI documents. Such disclosures will be shared with all individuals who prepare, review and approve ICSI documents.

No work group members have potential conflicts of interest to disclose.

## **ADAPTATION**

Measure was not adapted from another source.

## **RELEASE DATE**

2003 Apr

## **REVISION DATE**

2008 Oct

## **MEASURE STATUS**

This is the current release of the measure.

This measure updates a previous version: Institute for Clinical Systems Improvement (ICSI). Management of initial abnormal Pap smear. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2006 Oct. 32 p.

## **SOURCE(S)**

Institute for Clinical Systems Improvement (ICSI). Initial management of abnormal cervical cytology (Pap smear) and HPV testing. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2008 Oct. 32 p. [63 references]

## **MEASURE AVAILABILITY**

The individual measure, "Percentage of Adult Women Diagnosed with an Initial Abnormal Cervical Cytology of ASCUS with High-risk HPV Type Who Have Follow-up Colposcopy Within Six Months of Abnormality Identified," is published in "Health Care Guideline: Initial Management of Abnormal Cervical Cytology (Pap Smear) and HPV Testing." This document is available from the [Institute for Clinical Systems Improvement \(ICSI\) Web site](#).

For more information, contact ICSI at, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; phone: 952-814-7060; fax: 952-858-9675; Web site: [www.icsi.org](http://www.icsi.org); e-mail: [icsi.info@icsi.org](mailto:icsi.info@icsi.org).

## **NQMC STATUS**

This NQMC summary was completed by ECRI on February 9, 2004. This summary was updated by ECRI Institute on October 11, 2004, November 16, 2005, December 11, 2006, and again on November 26, 2008.

## **COPYRIGHT STATEMENT**

This NQMC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Measure) is based on the original measure, which is subject to the measure developer's copyright restrictions.

The abstracted ICSI Measures contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Measures are downloaded by an individual, the individual may not distribute copies to third parties.

If the abstracted ICSI Measures are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.

All other copyright rights in the abstracted ICSI Measures are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Measures.



## Disclaimer

### NQMC DISCLAIMER

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at <http://www.qualitymeasures.ahrq.gov/about/inclusion.aspx>.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. The inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.

© 2009 National Quality Measures Clearinghouse

Date Modified: 2/2/2009

